Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Eyenovia, Inc. (EYEN)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.1100+0.0100 (+0.48%)
At close: 04:00PM EST
Advertisement
Full screen
Loading interactive chart...
  • Benzinga

    Eyenovia's Optejet Shows Lower Proinflammatory Cytokines Levels, Chemokines Than Standard Drops

    Eyenovia Inc (NASDAQ: EYEN) announced results from a research study that evaluated the gene and protein expression of cytokines and chemokines after latanoprost+benzalkonium chloride (BAK) treatment administered via Optejet versus latanoprost+BAK administered via standard eye drops. Preservatives are used to support product sterility and prolong shelf-life. But patients treated with BAK preserved glaucoma medications often suffer inflammatory side effects. Related: HC Wainwright Initiates This E

  • GlobeNewswire

    Eyenovia Reveals Positive Evidence That Optejet® Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Drops

    Academic study found the Optejet® to be comparable to non-preserved drops in lessening the proinflammatory responseNEW YORK, Jan. 12, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced positive results from

  • GlobeNewswire

    Eyenovia Announces Participation at the 2023 International Consumer Electronics Show

    Booth to feature “smart” remote patient monitoring capabilities being developed for future versions of the company’s novel Optejet® drug delivery technology Company to occupy booth 8311 NEW YORK, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licen

Advertisement
Advertisement